RxDoctor Payments Data

Shyam Patel, DO

Family Medicine · Whiting, INNPI 1871974709

Payments from drug & device makers

$1,175in general payments, 2019–2025

Across 74 payments — averaging $15.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$374
  • Amgen$247
  • Kowa Pharmaceuticals America, Inc.$75
  • Novo Nordisk$53
  • Lilly USA, LLC$51
  • Exact Sciences$51
  • plus $323 from 16 others

What the payments were for

  • Food & beverage$1,175100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,175 in reported general payments places this provider in the 60th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$100,708
Medicare patients
158
Services billed
1,146

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide55$79,020
EliquisApixaban117$43,083
XareltoRivaroxaban129$41,376
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$24,158
EntrestoSacubitril/Valsartan22$14,826
Breo ElliptaFluticasone/Vilanterol22$14,215
TrulicityDulaglutide13$12,959
Spiriva RespimatTiotropium Bromide18$12,331
TradjentaLinagliptin37$9,346
Sevelamer Hcl13$9,032
Glucagon Emergency KitGlucagon29$8,311
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$6,811
Repatha SureclickEvolocumab12$6,707
Novolog FlexpenInsulin Aspart25$5,474
Atorvastatin Calcium478$5,311

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog Mix 70-30$53$80,62775 claims
PfizerEliquis, Prempro$21$45,508128 claims
GSKTrelegy Ellipta, Breo Ellipta$17$38,37362 claims
Boehringer IngelheimSpiriva Respimat, Tradjenta$16$21,67755 claims
NovartisEntresto$33$14,82622 claims
Lilly USA, LLCTrulicity$51$12,95913 claims
AbbVieSynthroid$16$1,54216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Whiting

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →